Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 19;19(1):2190690. doi: 10.1080/21645515.2023.2190690

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Moderna, Inc. Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

PMC Copyright notice

Figure 2. — Solicited (a) local and (b) systemic adverse reactions within 7 days of each dose. Percentages are based on participants in the solicited safety population, consisting of all randomly assigned participants receiving ≥1 dose and contributing any solicited adverse reaction data. Number of participants in the dose 1 solicited safety population: mRNA-1283 10 µg, n = 21; mRNA-1283 30 µg, n = 22; mRNA-1283 100 µg, n = 21; placebo + mRNA-1283 100 µg, n = 18; and mRNA-1273 100 µg, n = 22. Number of participants in the dose 2 solicited safety population: mRNA-1283 10 µg, n = 19; mRNA-1283 30 µg, n = 20; mRNA-1283 100 µg, n = 21; placebo + mRNA-1283 100 µg, n = 15; and mRNA-1273 100 µg, n = 20. Abbreviation: mRNA, messenger RNA.